Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for the treatment of substance abuse

A substance and drug delivery technology, applied in the directions of drug combinations, pharmaceutical formulations, active ingredients of heterocyclic compounds, etc., can solve the problems of not providing long-term treatment of symptoms, recurrent chronic opioid or ethanol addiction and dependence, etc.

Inactive Publication Date: 2003-03-26
艾伯特·舒尔曼
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when used alone, neither naltrexone nor acoprocet provide effective long-term treatment of these conditions, with frequent relapses over 3-12 months of chronic opioid or ethanol addiction and depend on

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for the treatment of substance abuse
  • Methods for the treatment of substance abuse
  • Methods for the treatment of substance abuse

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0104] Specifically, suitable combinations or combinations of naltrexone / acprocet / verapamil or amlodipine of the present invention include:

[0105] (a) naltrexone (12.5 mg) once daily, given together with: acamprosate in doses of 333 mg or 666 mg three times daily (or doses of ~1000 mg once or twice daily) and One sustained-release verapamil (80mg, 90mg, 120mg, 160mg, 180mg, 240mg, 320mg, 360mg or 480mg).

[0106] (b) naltrexone (25 mg) once daily, given together with: acoprocet in 333 mg or 666 mg doses three times daily (or ~1000 mg doses once or twice daily) and once daily Extended-release verapamil (80 mg, 90 mg, 120 mg, 160 mg, 180 mg, 240 mg, 320 mg, 360 mg, or 480 mg).

[0107] (c) naltrexone (50 mg) once daily, administered with the following drugs: three times daily doses of 333 mg or 666 mg acoprocet (or once or twice daily doses ~ 1000 mg) and once daily Extended-release verapamil (80 mg, 90 mg, 120 mg, 160 mg, 180 mg, 240 mg, 320 mg, 360 mg, or 480 mg).

[0108...

Embodiment 2

[0114] Suitable combinations or combinations of naltrexone / acprocet / felodipine or nifedipine according to the invention include:

[0115] (a) naltrexone (12.5 mg) once daily, given together with: acamprosate in doses of 333 mg or 666 mg three times daily (or doses of ~1000 mg once or twice daily) and One extended-release felodipine (2.5mg, 5mg, 7.5mg, 10mg, 15mg or 20mg).

[0116] (b) naltrexone (25 mg) once daily, given together with: acoprocet in 333 mg or 666 mg doses three times daily (or ~1000 mg doses once or twice daily) and once daily Extended release felodipine (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg).

[0117] (c) naltrexone (50 mg) once daily, administered with the following drugs: three times daily doses of 333 mg or 666 mg acoprocet (or once or twice daily doses ~ 1000 mg) and once daily Extended release felodipine (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg).

[0118] (d) naltrexone (100 mg) once daily, given together with: acoprocet in doses of 333 mg o...

Embodiment 3

[0124] The combination or composition of naltrexone / acprosate / nitrendipine or nicardipine or nisoldipine of the present invention comprises:

[0125](a) 12.5 mg naltrexone per day and acoprocet in 333 mg or 666 mg doses three times a day (or ~1000 mg doses once or twice a day) and 5 mg, 10 mg, 15 mg once or twice a day Or 20mg long-acting nitrendipine.

[0126] (b) naltrexone 25 mg daily and acoprocet in doses of 333 mg or 666 mg three times daily (or doses of ~1000 mg once or twice daily) and 5 mg, 10 mg, 15 mg or 20 mg of long-acting nitrendipine.

[0127] (c) naltrexone 50 mg per day and acoprocet in doses of 333 mg or 666 mg three times per day (or once or twice daily to 1000 mg doses) and 5 mg, 10 mg, 15 mg or 20 mg of long-acting nitrendipine once or twice daily.

[0128] (d) naltrexone 100 mg daily and acoprocet in doses of 333 mg or 666 mg three times daily (or once or twice daily doses to 1000 mg) and once or twice daily 5 mg, 10 mg, 15 mg or 20 mg of long-acting ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods of therapy for substance addiction comprising the administration to a subject in need thereof a combination of: (i) a mu-opioid receptor antagonist; (ii) a calcium channel blocker which is long-acting or in sustained-release form or which is nimodipine in rapid release form; and (iii) an NMDA glutamate receptor modulator; as well as combinations, kits and composition useful therefor.

Description

field of invention [0001] The present invention relates generally to methods of treatment and combinations and compositions suitable therefor. In particular, the invention relates to methods of treating substance abuse, including alcohol and opiate addiction. Background of the invention [0002] Substance addiction involves an overwhelming and uncontrollable physical and psychological craving for a specific substance such as alcohol, heroin, morphine, methadone, nicotine, amphetamines, solvent inhalants, cocaine, or cannabis, and can cause addicts and Groups carry enormous social and monetary costs. In many cases, withdrawal of this substance without adjunctive therapy can lead to acute physical and psychiatric illness. Attempts to treat substance addiction, such as psychotherapy, behavior modification, or certain other drug therapies, have met with limited success, with many addicts relapsing into chronic use. [0003] The powerful and potent competitive and specific CNS...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/16A61K31/185A61K31/222A61K31/4422A61K31/485A61K31/55A61K45/06A61P25/30A61P25/32A61P25/34A61P25/36
CPCA61K31/16A61K45/06A61K31/485A61P25/30A61P25/32A61P25/34A61P25/36A61K2300/00A61K31/4422
Inventor 艾伯特·舒尔曼
Owner 艾伯特·舒尔曼
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com